Published online Feb 16, 2026. doi: 10.4253/wjge.v18.i2.114400
Revised: November 9, 2025
Accepted: January 4, 2026
Published online: February 16, 2026
Processing time: 138 Days and 20.2 Hours
The clinical management of small gastric submucosal tumors originating from the muscularis propria layer is a non-negligible challenge. We have proposed a safe and simple method called precutting endoscopic band ligation (EBL).
To assess the long-term viability of endoscopic submucosal dissection (ESD) and precutting EBL and clarify precutting EBL’s safety and efficacy.
In this retrospective study, 94 patients with small gastric muscularis propria tumors underwent ESD or precutting EBL at a tertiary hospital. Patient demo
We reviewed 94 patients with gastric submucosal tumors originating from the muscularis propria layer (< 20 mm), including 48 treated by ESD and 46 by precutting EBL. No local recurrences were detected in either group during follow-up, and the median follow-up period was 48.60 months (interquartile range: 48.00-60.00) in the ESD group and 52.00 months (interquartile range: 36.00-84.00) in the precutting EBL group. However, precutting EBL was significantly superior in terms of operative time (46 minutes vs 17 minutes, P < 0.001) and the AE rate (11.47% vs 0%, P = 0.024).
Precutting EBL had a shorter operative time than ESD and was associated with no AEs. Future randomized controlled studies are required to confirm the feasibility of this approach.
Core Tip: This article compared endoscopic submucosal dissection and precutting endoscopic band ligation (EBL) for gastric submucosal tumors < 20 mm originating from the muscularis propria. Both techniques achieved excellent long-term tumor control without recurrence, but precutting EBL demonstrated significant advantages, including a shorter operative time and fewer adverse events. These findings suggest that precutting EBL is a safer, simpler, and more efficient alternative to endoscopic submucosal dissection, warranting further validation in prospective randomized controlled trials.
